Restructuring is fun, right? Employees at Novartis are about to find out. That’s because Novartis is splitting into two business units with one focusing on oncology (Novartis Oncology) and the other focusing on just about everything else (Novartis Pharmaceuticals). The move comes as the company now has, thanks to its bringing on board GSK’s oncology assets, enough oncology assets to warrant a separate business unit. What is unclear from published reports is where within the company the split occurs. For example, are drug discovery, preclinical, clinical development, and commercial operations all aligned within a business unit or are some of these still “shared” resources between the units? Nobody likes a restructuring, not the employees and especially not service providers. Here’s hoping your Novartis rolodex is in pencil.